Global influenza spending is being shaped by a $5.0 billion influenza diagnostics market in 2023 alongside a $3.6 billion influenza vaccine market, yet the real-world impact is measured in how much vaccination cuts illness and hospital risk. Cochrane pooled evidence points to a 37% reduction in influenza illness for vaccinated people, while some cohort claims research finds a 2.5% lower probability of hospitalization. Pricing, wastage assumptions, and ICER ranges move in the same direction but not always the way you might expect, making this a dataset worth reading closely.
Key Takeaways
- $5.0 billion global influenza diagnostics market size in 2023, supporting flu surveillance and testing expenditures.
- $3.6 billion global influenza vaccine market size in 2023 (with growth forecasts tied to seasonal demand and pandemic preparedness).
- $7.3 billion global influenza vaccine market size estimate for 2024 in a segment-focused industry forecast.
- 37% reduction in influenza illness among vaccinated individuals compared with unvaccinated in a pooled estimate across randomized and observational studies summarized by the Cochrane review evidence base.
- 39% reduction in risk of influenza-related medically attended illness in vaccinated people in a meta-analysis of observational studies (pooled effectiveness across seasons).
- 15% reduction in all-cause mortality among older adults in some meta-analyses is associated with influenza vaccination (range depends on study design and season).
- 50% of the population coverage achieved in targeted groups reduces influenza transmission in modeling analyses used by public health agencies (coverage sensitivity in transmission models).
- Vaccination reduces influenza-confirmed illness risk compared with placebo in randomized trials; a pooled relative risk reduction of about 59% is reported for children in older meta-analyses (evidence synthesis).
- 2.0–3.0 fold rise in post-vaccination antibody titers is used as a criterion for seroconversion in many influenza vaccine immunogenicity studies (endpoint used in trials).
- 38% of adults in the UK reported receiving a flu vaccine in the 2023–2024 season for eligible groups (NHS/UK uptake reporting).
- $2.0–$3.0 per dose wholesale cost range in some healthcare procurement contexts for trivalent influenza vaccines in recent procurement analyses (cost metric depends on country and formulation).
- $10–$30 per dose retail/pharmacy pricing range is reported in U.S. price research sources for influenza vaccine products (price varies by formulation and setting).
- 2%–5% wastage rate is used as an assumption in economic evaluations of vaccination programs in multiple published cost-effectiveness models (wastage assumption).
- In a 2021 peer-reviewed economic evaluation synthesis, influenza vaccination programs can be cost-effective with ICERs often below common willingness-to-pay thresholds in older adults and risk groups (cost-effectiveness synthesis quantitative results).
Flu vaccination reduces illness and hospitalizations while remaining cost effective, with benefits supported by major studies.
Related reading
01 · Category
Market Size5 stats
01
$5.0 billion global influenza diagnostics market size in 2023, supporting flu surveillance and testing expenditures.
02
$3.6 billion global influenza vaccine market size in 2023 (with growth forecasts tied to seasonal demand and pandemic preparedness).
03
$7.3 billion global influenza vaccine market size estimate for 2024 in a segment-focused industry forecast.
04
$1.9 billion total market value for influenza antiviral drugs in 2023 reported by an industry market-analytics firm (demand influenced by flu seasons).
05
$4.1 billion estimated global flu vaccine market revenue in 2022 reported by another industry forecast provider (regional and brand mix drivers).
Interpretation
Market Size Interpretation
The market size data show influenza healthcare remains substantial and growing, with the global flu vaccine market reaching about $7.3 billion in 2024 after $3.6 billion in 2023, indicating strong and increasing demand reflected in the broader flu surveillance, diagnostics, and treatment spend of $5.0 billion and $1.9 billion respectively.
02 · Category
Public Health Impact5 stats
01
37% reduction in influenza illness among vaccinated individuals compared with unvaccinated in a pooled estimate across randomized and observational studies summarized by the Cochrane review evidence base.
02
39% reduction in risk of influenza-related medically attended illness in vaccinated people in a meta-analysis of observational studies (pooled effectiveness across seasons).
03
15% reduction in all-cause mortality among older adults in some meta-analyses is associated with influenza vaccination (range depends on study design and season).
04
10% absolute reduction in laboratory-confirmed influenza infection has been reported in certain matched vaccine contexts in randomized community trials (example pooled trial result).
05
3.0%–5.0% annual attack rate among high-risk pediatric groups can be reduced by vaccination in observed outbreaks (varies by setting).
Interpretation
Public Health Impact Interpretation
From a public health impact perspective, flu vaccination consistently lowers illness and healthcare burden, cutting influenza illness by 37% among vaccinated people and reducing influenza related medically attended illness by 39% across studies, with additional population level benefits such as a 15% reduction in all cause mortality among older adults in some meta analyses.
03 · Category
Vaccine Effectiveness6 stats
01
50% of the population coverage achieved in targeted groups reduces influenza transmission in modeling analyses used by public health agencies (coverage sensitivity in transmission models).
02
Vaccination reduces influenza-confirmed illness risk compared with placebo in randomized trials; a pooled relative risk reduction of about 59% is reported for children in older meta-analyses (evidence synthesis).
03
2.0–3.0 fold rise in post-vaccination antibody titers is used as a criterion for seroconversion in many influenza vaccine immunogenicity studies (endpoint used in trials).
04
In a 2023 peer-reviewed review, influenza vaccination was associated with a reduction in influenza-related hospitalizations by 27% in pooled estimates across observational evidence (systematic review effect estimate).
05
In a 2019 systematic review of observational studies, influenza vaccination reduced laboratory-confirmed influenza infection by about 30% overall (pooled effectiveness estimate reported in the review).
06
In a large U.S. claims-based cohort study, influenza vaccination was associated with 2.5% lower probability of hospitalization among vaccinated patients compared with unvaccinated (absolute difference reported).
Interpretation
Vaccine Effectiveness Interpretation
Overall, across both modeling and real world evidence, flu vaccines show moderate but consistent protection, cutting influenza related hospitalization by 27% and laboratory confirmed infection by about 30%, with children in trials seeing a pooled 59% reduction in influenza confirmed illness risk compared with placebo.
More related reading
04 · Category
Vaccine Uptake1 stats
01
38% of adults in the UK reported receiving a flu vaccine in the 2023–2024 season for eligible groups (NHS/UK uptake reporting).
Interpretation
Vaccine Uptake Interpretation
In the Vaccine Uptake category, only 38% of eligible UK adults reported getting a flu vaccine in the 2023–2024 season, showing that uptake remains relatively low despite eligibility.
05 · Category
Cost & Pricing7 stats
01
$2.0–$3.0 per dose wholesale cost range in some healthcare procurement contexts for trivalent influenza vaccines in recent procurement analyses (cost metric depends on country and formulation).
02
$10–$30 per dose retail/pharmacy pricing range is reported in U.S. price research sources for influenza vaccine products (price varies by formulation and setting).
03
2%–5% wastage rate is used as an assumption in economic evaluations of vaccination programs in multiple published cost-effectiveness models (wastage assumption).
04
QALY and hospitalization-avoidance are the primary effectiveness inputs in cost-effectiveness models for influenza vaccination; studies often report ICERs below common willingness-to-pay thresholds in risk groups (economic evaluation output).
05
ICERs are reported in some health-economic analyses in the range of $10,000–$50,000 per QALY gained for influenza vaccination of elderly in certain settings (varies by country and assumptions).
06
1.0 to 1.5% reduction in medical spending attributed to influenza vaccination in some budget-impact studies (modeled spending impact metric).
07
$25–$60 per dose is the public listed price of influenza vaccine types in certain U.S. retail settings reported by consumer price tracking analyses (price context metric).
Interpretation
Cost & Pricing Interpretation
Across recent analyses, wholesale costs for trivalent flu vaccines often run about $2.0 to $3.0 per dose while U.S. retail pricing commonly lands around $10 to $30 per dose, and even after accounting for modeled 2% to 5% wastage, studies frequently find vaccination value via ICERs such as $10,000 to $50,000 per QALY gained, underscoring how pricing markups still translate into cost effectiveness within the Cost and Pricing frame.
06 · Category
Policy And Economics1 stats
01
In a 2021 peer-reviewed economic evaluation synthesis, influenza vaccination programs can be cost-effective with ICERs often below common willingness-to-pay thresholds in older adults and risk groups (cost-effectiveness synthesis quantitative results).
Interpretation
Policy And Economics Interpretation
A 2021 peer reviewed economic evaluation synthesis found that influenza vaccination programs are often cost effective in older adults and risk groups, with ICERs commonly falling below standard willingness to pay thresholds, underscoring strong policy and economics support for expanding coverage in these populations.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Flu Vaccine Statistics. Gitnux. https://gitnux.org/flu-vaccine-statistics
MLA
Rachel Svensson. "Flu Vaccine Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/flu-vaccine-statistics.
Chicago
Rachel Svensson. 2026. "Flu Vaccine Statistics." Gitnux. https://gitnux.org/flu-vaccine-statistics.
Sources & references
25 datasets cited across this report · attribution is report-level
+8 additional datasets cited (not shown individually)